Search Within

Neeta Pandit-Taskar

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (24)
Groups
  1. Department of Medicine (52)
  2. Genitourinary Oncology Service (52)
  3. Molecular Imaging and Therapy Service (52)
  4. Radiology, Department of (52)
  5. Solid Tumor Oncology Division (52)
  6. GSK Faculty (39)

More Groups

People
  1. Michael Morris (45)
  2. Steven Larson (35)
  3. Howard Scher (32)
  4. Jorge Carrasquillo (26)
  5. Joseph O'Donoghue (25)
  6. Serge Lyashchenko (15)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (2)
  5. 2021 (3)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (24)
  2. Journal of Nuclear Medicine (10)
  3. Clinical Cancer Research (5)
  4. European Journal of Nuclear Medicine and Molecular Imaging (3)
  5. Cancer (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (24)
  2. Society of Nuclear Medicine (10)
  3. American Association for Cancer Research (7)
  4. Springer (6)
  5. Elsevier Inc. (2)
  6. American Chemical Society (1)

More Publishers

Results (52)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 0 study to assess the biodistribution and pharmacokinetics of a radiolabeled antibody targeting human kallikrein 2 in participants with metastatic castration-resistant prostate cancer
    Journal Article

    Pandit-Taskar, N.; O'Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Ilovich, O.; Russell, M.; Nyima, T.; Divgi, C. R.; Yu, M.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer
    Meeting Abstract

    Morris, M. J.; Sartor, A. O.; Wong, J. Y. C.; Max, S. I.; Xie, H.; Yu, A.; Divgi, C. R.; Patricia, D.; Avadhani, A. N.; Pandit-Taskar, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II, nonrandomized open trial assessing pain efficacy with radium-223 in symptomatic metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D.; Tagawa, S.; Moryl, N.; Milowsky, M.; Heller, G.; Osborne, J.; Rathkopf, D.; Basch, E.; Pandit-Taskar, N.; Morris, M. J.
    Clinical Genitourinary Cancer (2021)

    Fulltext@MSK | Save
  • Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy
    Meeting Abstract

    Morris, M. J.; O' Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Russell, M.; Nyima, T.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase 0 study to assess [111In]-DOTA-h11B6 to target -human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; O'Donoghue, J. A.; Chetty, D.; Russell, M.; Zulch, E.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save